Avanza Fonder AB Purchases Shares of 36,065 Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Avanza Fonder AB purchased a new stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 36,065 shares of the company's stock, valued at approximately $421,000.

A number of other institutional investors have also bought and sold shares of the company. American Century Companies Inc. grew its position in shares of Intellia Therapeutics by 23.8% during the 2nd quarter. American Century Companies Inc. now owns 330,514 shares of the company's stock worth $7,397,000 after buying an additional 63,550 shares during the period. Dimensional Fund Advisors LP boosted its stake in Intellia Therapeutics by 8.1% during the second quarter. Dimensional Fund Advisors LP now owns 1,324,561 shares of the company's stock worth $29,648,000 after acquiring an additional 98,865 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Intellia Therapeutics in the second quarter worth $866,000. Hsbc Holdings PLC increased its stake in Intellia Therapeutics by 6.0% in the second quarter. Hsbc Holdings PLC now owns 36,631 shares of the company's stock valued at $813,000 after purchasing an additional 2,067 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. raised its holdings in shares of Intellia Therapeutics by 6,974.7% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 60,913 shares of the company's stock valued at $1,363,000 after purchasing an additional 60,052 shares during the period. Institutional investors own 88.77% of the company's stock.

Intellia Therapeutics Stock Performance

NTLA stock traded up $0.08 during mid-day trading on Monday, hitting $9.50. The company had a trading volume of 3,327,352 shares, compared to its average volume of 2,148,948. Intellia Therapeutics, Inc. has a 12 month low of $9.25 and a 12 month high of $34.87. The stock's fifty day moving average price is $12.99 and its two-hundred day moving average price is $18.38. The firm has a market cap of $967.58 million, a PE ratio of -1.75 and a beta of 1.83.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($1.34) EPS for the quarter, beating the consensus estimate of ($1.37) by $0.03. The firm had revenue of $9.10 million during the quarter, compared to analysts' expectations of $8.28 million. During the same quarter in the previous year, the company posted ($1.38) EPS. Intellia Therapeutics's revenue for the quarter was down 24.1% on a year-over-year basis. Equities analysts anticipate that Intellia Therapeutics, Inc. will post -5.11 earnings per share for the current year.

Wall Street Analysts Forecast Growth

NTLA has been the topic of a number of research reports. Citigroup dropped their price target on Intellia Therapeutics from $25.00 to $19.00 and set a "neutral" rating on the stock in a research note on Friday, October 25th. The Goldman Sachs Group cut their target price on Intellia Therapeutics from $19.00 to $12.00 and set a "neutral" rating on the stock in a report on Tuesday, January 14th. StockNews.com upgraded shares of Intellia Therapeutics to a "sell" rating in a research note on Friday, November 8th. Wedbush reaffirmed a "neutral" rating and issued a $10.00 price objective (down from $14.00) on shares of Intellia Therapeutics in a research note on Friday, January 10th. Finally, Oppenheimer reduced their price objective on shares of Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a report on Monday, January 13th. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $51.06.

Insider Buying and Selling

In other news, CEO John M. Leonard sold 26,807 shares of the firm's stock in a transaction on Friday, January 3rd. The stock was sold at an average price of $12.18, for a total value of $326,509.26. Following the completion of the transaction, the chief executive officer now directly owns 941,115 shares of the company's stock, valued at $11,462,780.70. This trade represents a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In the last 90 days, insiders sold 28,735 shares of company stock valued at $349,909. 3.20% of the stock is owned by insiders.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.